|
Volumn 8, Issue 6, 2002, Pages 547-550
|
Targeting the endocannabinoid system in cancer therapy: A call for further research
|
Author keywords
[No Author keywords available]
|
Indexed keywords
2 ARACHIDONOYLGLYCEROL;
3 FLUOROANANDAMIDE;
ANANDAMIDE;
ARVANIL;
CANNABINOID;
CANNABINOID 1 RECEPTOR;
CANNABINOID 2 RECEPTOR;
CANNABINOID RECEPTOR;
CANNABINOID RECEPTOR AFFECTING AGENT;
CANNABINOID RECEPTOR AGONIST;
CANNABIS;
DRONABINOL;
NABILONE;
PARTIAL AGONIST;
TETRAHYDROCANNABINOL;
UNCLASSIFIED DRUG;
VANILLOID RECEPTOR;
VANILLOID RECEPTOR STIMULATING AGENT;
ANTINEOPLASTIC ACTIVITY;
CANCER INHIBITION;
CANCER RESEARCH;
CANCER THERAPY;
DRUG DEPENDENCE;
DRUG MECHANISM;
DRUG TARGETING;
DRUG TOLERANCE;
HUMAN;
NAUSEA;
NONHUMAN;
PRIORITY JOURNAL;
REVIEW;
TUMOR GROWTH;
VOMITING;
ANTINEOPLASTIC AGENTS;
APOPTOSIS;
BRAIN;
CANNABINOIDS;
CELL DIVISION;
ENDOCANNABINOIDS;
HUMANS;
NEOPLASMS;
RECEPTORS, CANNABINOID;
RECEPTORS, DRUG;
CANNABIS;
CANNABIS SATIVA;
|
EID: 0036278032
PISSN: 10788956
EISSN: None
Source Type: Journal
DOI: 10.1038/nm0602-547 Document Type: Review |
Times cited : (160)
|
References (30)
|